



Correction

# Correction: Xingchen Zhou, et al. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. *Int. J. Mol. Sci.* **2017**, *18*, 295

Xingchen Zhou <sup>1,2,3</sup>, Yijing He <sup>2,3</sup>, Yehong Kuang <sup>2,3</sup>, Jie Li <sup>2,3</sup>, Jianglin Zhang <sup>2,3</sup>, Mingliang Chen <sup>2,3</sup>, Wangqing Chen <sup>2,3</sup>, Juan Su <sup>2,3</sup>, Shuang Zhao <sup>2,3</sup>, Panpan Liu <sup>2,3</sup>, Menglin Chen <sup>2,3</sup>, Minxue Shen <sup>2,3</sup>, Xiaoping Chen <sup>1</sup>, Wu Zhu <sup>2,3,\*</sup> and Xiang Chen <sup>2,3,\*</sup>

<sup>1</sup> Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; zhouxingchen117@163.com (X.Z.); chenxp74@hotmail.com (X.C.)

<sup>2</sup> Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; yijing.he@foxmail.com (Y.H.); yh\_927@126.com (Y.K.); xylj@medmail.com.cn (J.L.); leozjl1010@126.com (J.Z.); chenmingliang@medmail.com.cn (M.C.); lanchen2008@163.com (W.C.); sujuanderm@csu.edu.cn (J.S.); shuangxy@sina.com (S.Z.); liupanpan91@hotmail.com (P.L.); mollychen249821543@163.com (M.C.); shenmx1988@gmail.com (M.S.)

<sup>3</sup> Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha 410008, China

\* Correspondence: zhuwu70@hotmail.com (W.Z.); chenxiangck@126.com (X.C.); Tel.: +86-133-1950-9308 (W.Z.); +86-139-7585-5322 (X.C.)

Received: 10 July 2017; Accepted: 10 July 2017; Published: 4 September 2017

We would like to submit the following correction to the published paper [1], the reason for this action is that the data in Table 3 were reanalyzed by one more accurate statistic method: On page 12, the sentence of paragraph three “OR and 95% CI were calculated by limited backward-LR (likelihood ratio) logistic regression analysis with adjustment by clinical variables” should be corrected into “OR and 95% CI were calculated by limited enter logistic regression analysis with adjustment by clinical variables”. The corrections resulted some changes in Table 3 and related data in text, while the significance and the conclusions remained unchanged. Furthermore, in order to make the reader easy to understand the data in Table 3, we revised the table title and added notes for Table 3 (page 7).

Table 3 should be replaced:

**Table 3.** Multivariate logistic regression analysis of four positive SNPs.

| Gene   | SNPs       | Genotypes/<br>Alleles | PASI < 75  | PASI ≥ 75 | Adjusted OR <sup>1</sup><br>[95% CI] | p Value      |
|--------|------------|-----------------------|------------|-----------|--------------------------------------|--------------|
|        |            |                       | n = 100    | n = 66    |                                      |              |
| CRB2   | rs1105223  | TT, n (%)             | 40 (42.6)  | 23 (37.1) | 1.00                                 |              |
|        |            | CT, n (%)             | 31 (33)    | 33 (53.2) | 2.012 [0.710–5.706]                  | 0.188        |
|        |            | CC, n (%)             | 23 (24.4)  | 6 (9.7)   | 4.098 [1.461–11.493]                 | <b>0.007</b> |
|        |            | CT/CC, n (%)          | 54 (57.4)  | 39 (62.9) | 1.363 [0.679–2.735]                  | 0.383        |
|        |            | TT/CT, n (%)          | 71 (75.5)  | 56 (90.3) | 0.588 [0.363–0.955]                  | <b>0.032</b> |
|        |            | T, n (%)              | 111 (59)   | 79 (63.7) | 1.00                                 |              |
|        |            | C, n (%)              | 77 (41)    | 45 (36.3) | 1.118 [0.687–1.820]                  | 0.652        |
| ANKLE1 | rs11086065 | AA, n (%)             | 33 (33.7)  | 36 (56.3) | 1.00                                 |              |
|        |            | AG, n (%)             | 50 (51)    | 22 (34.3) | 2.552 [0.876–7.439]                  | 0.086        |
|        |            | GG, n (%)             | 15 (15.3)  | 6 (9.4)   | 0.905 [0.303–2.700]                  | 0.858        |
|        |            | AG/GG, n (%)          | 65 (66.3)  | 28 (43.8) | 2.756 [1.415–5.368]                  | <b>0.003</b> |
|        |            | AA/AG, n (%)          | 83 (84.7)  | 58 (90.6) | 0.815 [0.485–1.369]                  | 0.439        |
|        |            | A, n (%)              | 116 (59.2) | 94 (73.4) | 1.00                                 |              |
|        |            | G, n (%)              | 80 (40.8)  | 34 (26.6) | 1.939 [1.171–3.210]                  | <b>0.010</b> |

|         |           |                     |            |           |                     |              |
|---------|-----------|---------------------|------------|-----------|---------------------|--------------|
| ARHGEF3 | rs3821414 | TT, <i>n</i> (%)    | 51 (51)    | 18 (27.3) | 1.00                |              |
|         |           | CT, <i>n</i> (%)    | 39 (39)    | 34 (51.5) | 0.253 [0.095–0.675] | <b>0.006</b> |
|         |           | CC, <i>n</i> (%)    | 10 (10)    | 14 (21.2) | 0.568 [0.222–1.451] | 0.237        |
|         |           | CT/CC, <i>n</i> (%) | 49 (49)    | 48 (72.7) | 0.386 [0.194–0.765] | <b>0.006</b> |
|         |           | TT/CT, <i>n</i> (%) | 90 (90)    | 52 (78.8) | 1.593 [1.024–2.479] | <b>0.039</b> |
| SFRP4   | rs1802073 | T, <i>n</i> (%)     | 141 (70.5) | 70 (53)   | 1.00                |              |
|         |           | C, <i>n</i> (%)     | 59 (29.5)  | 62 (47)   | 0.487 [0.305–0.779] | <b>0.003</b> |
|         |           | GG, <i>n</i> (%)    | 14 (14)    | 7 (10.6)  | 1.00                |              |
|         |           | GT, <i>n</i> (%)    | 60 (60)    | 28 (42.4) | 0.483 [0.167–1.394] | 0.178        |
|         |           | TT, <i>n</i> (%)    | 26 (26)    | 31 (47)   | 0.402 [0.199–0.812] | <b>0.011</b> |
|         |           | GT/TT, <i>n</i> (%) | 86 (86)    | 59 (89.4) | 0.797 [0.296–2.149] | 0.797        |
|         |           | GG/GT, <i>n</i> (%) | 74 (74)    | 35 (53)   | 2.400 [1.226–4.696] | <b>0.011</b> |
|         |           | G, <i>n</i> (%)     | 88 (44)    | 42 (31.8) | 1.00                |              |
|         |           | T, <i>n</i> (%)     | 112 (56)   | 90 (68.2) | 0.612 [0.380–0.984] | <b>0.043</b> |

<sup>1</sup> adjusted for age, gender and BMI. Bold and italics in *p* value mean the significant result.

with

**Table 3.** Association of four positive SNPs with response to acitretin via logistic regression analysis.

| Gene    | SNPs                    | Genotypes/<br>Alleles | PASI < 75      | PASI ≥ 75     | Adjusted OR <sup>1</sup><br>[95% CI] | <i>p</i> Value |
|---------|-------------------------|-----------------------|----------------|---------------|--------------------------------------|----------------|
|         |                         |                       | <i>n</i> = 100 | <i>n</i> = 66 |                                      |                |
| CRB2    | rs1105223 <sup>a</sup>  | TT, <i>n</i> (%)      | 40 (42.6)      | 23 (37.1)     | 1.00                                 |                |
|         |                         | CT, <i>n</i> (%)      | 31 (33)        | 33 (53.2)     | 0.498 [0.234–1.062]                  | 0.071          |
|         |                         | CC, <i>n</i> (%)      | 23 (24.4)      | 6 (9.7)       | 1.852 [0.640–5.359]                  | 0.256          |
|         |                         | CT/CC, <i>n</i> (%)   | 54 (57.4)      | 39 (62.9)     | 0.734 [0.366–1.472]                  | 0.383          |
|         |                         | TT/CT, <i>n</i> (%)   | 71 (75.5)      | 56 (90.3)     | 0.371 [0.139–1.085] <sup>2</sup>     | <b>0.048</b>   |
|         |                         | T, <i>n</i> (%)       | 111 (59)       | 79 (63.7)     | 1.00                                 |                |
| ANKLE1  | rs11086065 <sup>b</sup> | C, <i>n</i> (%)       | 77 (41)        | 45 (36.3)     | 1.118 [0.687–1.820]                  | 0.652          |
|         |                         | AA, <i>n</i> (%)      | 33 (33.7)      | 36 (56.3)     | 1.00                                 |                |
|         |                         | AG, <i>n</i> (%)      | 50 (51)        | 22 (34.3)     | 2.922 [1.413–6.041]                  | <b>0.004</b>   |
|         |                         | GG, <i>n</i> (%)      | 15 (15.3)      | 6 (9.4)       | 2.553 [0.851–7.652]                  | 0.094          |
|         |                         | AG/GG, <i>n</i> (%)   | 65 (66.3)      | 28 (43.8)     | 2.835 [1.436–5.600]                  | <b>0.003</b>   |
|         |                         | AA/AG, <i>n</i> (%)   | 83 (84.7)      | 58 (90.6)     | 0.664 [0.235–1.875] <sup>3</sup>     | 0.439          |
| ARHGEF3 | rs3821414               | A, <i>n</i> (%)       | 116 (59.2)     | 94 (73.4)     | 1.00                                 |                |
|         |                         | G, <i>n</i> (%)       | 80 (40.8)      | 34 (26.6)     | 1.966 [1.181–3.271]                  | <b>0.009</b>   |
|         |                         | TT, <i>n</i> (%)      | 51 (51)        | 18 (27.3)     | 1.00                                 |                |
|         |                         | CT, <i>n</i> (%)      | 39 (39)        | 34 (51.5)     | 0.464 [0.222–0.968]                  | <b>0.041</b>   |
|         |                         | CC, <i>n</i> (%)      | 10 (10)        | 14 (21.2)     | 0.256 [0.098–0.713]                  | <b>0.009</b>   |
|         |                         | CT/CC, <i>n</i> (%)   | 49 (49)        | 48 (72.7)     | 0.402 [0.201–0.805]                  | <b>0.01</b>    |
| SFRP4   | rs1802073               | TT/CT, <i>n</i> (%)   | 90 (90)        | 52 (78.8)     | 2.465 [1.011–6.013] <sup>4</sup>     | <b>0.047</b>   |
|         |                         | T, <i>n</i> (%)       | 141 (70.5)     | 70 (53)       | 1.00                                 |                |
|         |                         | C, <i>n</i> (%)       | 59 (29.5)      | 62 (47)       | 0.497 [0.310–0.797]                  | <b>0.004</b>   |
|         |                         | GG, <i>n</i> (%)      | 14 (14)        | 7 (10.6)      | 1.00                                 |                |
|         |                         | GT, <i>n</i> (%)      | 60 (60)        | 28 (42.4)     | 1.196 [0.421–3.396]                  | 0.737          |
|         |                         | TT, <i>n</i> (%)      | 26 (26)        | 31 (47)       | 0.449 [0.153–1.321]                  | 0.146          |
|         |                         | GT/TT, <i>n</i> (%)   | 86 (86)        | 59 (89.4)     | 0.797 [0.296–2.149]                  | 0.655          |
|         |                         | GG/GT, <i>n</i> (%)   | 74 (74)        | 35 (53)       | 2.570 [1.294–5.107] <sup>5</sup>     | <b>0.007</b>   |
|         |                         | G, <i>n</i> (%)       | 88 (44)        | 42 (31.8)     | 1.00                                 |                |
|         |                         | T, <i>n</i> (%)       | 112 (56)       | 90 (68.2)     | 0.603 [0.374–0.971]                  | <b>0.037</b>   |

<sup>1</sup> adjusted for age, gender and BMI, OR < 1 means response to acitretin, OR > 1 means non-response to acitretin; <sup>2</sup> compared to the CC genotype; <sup>3</sup> compared to the GG genotype; <sup>4</sup> compared to the CC genotype; <sup>5</sup> compared to the TT genotype; <sup>a</sup> total of 156 samples were detected; <sup>b</sup> total of 162 samples were detected; Bold and italics in *p* value mean the significant result.

In addition, there were some writing errors: “rs1802073T>G” should be corrected into “rs1802073G>T” (in Abstract, and page 10, paragraph 1 and page 11, paragraph 5). According to the contribution, the affiliation order was corrected: “Department of Clinical Pharmacology, Xiangya Hospital, Central South University” was corrected into the first affiliation.

These changes have no material impact on the conclusions of our paper. The manuscript will be updated and the original will remain online on the article webpage. We apologize for any inconvenience caused to our readers.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Zhou, X.; He, Y.; Kuang, Y.; Li, J.; Zhang, J.; Chen, M.; Chen, W.; Su, J.; Zhao, S.; Liu, P.; et al. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. *Int. J. Mol. Sci.* **2017**, *18*, 295; doi:10.3390/ijms18020295.



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).